Disruptive reproductive technologies

I Glenn Cohen¹, George Q Daley^{2

3}, Eli Y Adashi⁴

Affiliations

¹ Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Harvard Law School, Cambridge, MA 02138, USA. igcohen@law.harvard.edu.
² Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.
³ Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
⁴ The Warren Alpert Medical School, Brown University, Providence, RI 02906, USA.

I Glenn Cohen et al. Sci Transl Med. 2017.

. 2017 Jan 11;9(372):eaag2959.

doi: 10.1126/scitranslmed.aag2959.

I Glenn Cohen¹, George Q Daley^{2

3}, Eli Y Adashi⁴

¹ Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Harvard Law School, Cambridge, MA 02138, USA. igcohen@law.harvard.edu.
² Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.
³ Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
⁴ The Warren Alpert Medical School, Brown University, Providence, RI 02906, USA.

Abstract

In vitro gametogenesis raises new possibilities for reproductive and regenerative medicine as well as vexing policy challenges.